Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.
Niyomnaitham S, Toh ZQ, Licciardi PV, Wongprompitak P, Srisutthisamphan K, Copeland KK, Chokephaibulkit K. Niyomnaitham S, et al. J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.014. Epub 2022 Jun 18. J Infect. 2022. PMID: 35728642 Free PMC article. Clinical Trial. No abstract available.
Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers.
Angkasekwinai N, Sewatanon J, Niyomnaitham S, Phumiamorn S, Sukapirom K, Sapsutthipas S, Sirijatuphat R, Wittawatmongkol O, Senawong S, Mahasirimongkol S, Trisiriwanich S, Chokephaibulkit K. Angkasekwinai N, et al. Among authors: niyomnaitham s. Vaccine X. 2022 Mar 5;10:100153. doi: 10.1016/j.jvacx.2022.100153. eCollection 2022 Apr. Vaccine X. 2022. PMID: 35282410 Free PMC article.
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Niyomnaitham S, et al. Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865. doi: 10.1080/21645515.2022.2091865. Epub 2022 Jul 11. Hum Vaccin Immunother. 2022. PMID: 35816053 Free PMC article. Clinical Trial.
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.
Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, Rattanasompattikul M, Mahasirimongkol S, Wichukchinda N, Chokephaibulkit K. Sirijatuphat R, et al. Among authors: niyomnaitham s. Emerg Microbes Infect. 2022 Dec;11(1):2197-2206. doi: 10.1080/22221751.2022.2117092. Emerg Microbes Infect. 2022. PMID: 35997325 Free PMC article. Clinical Trial.
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.
Chatsiricharoenkul S, Niyomnaitham S, Posen HJ, Toh ZQ, Licciardi PV, Wongprompitak P, Duangchinda T, Pakchotanon P, Chantima W, Chokephaibulkit K. Chatsiricharoenkul S, et al. Among authors: niyomnaitham s. Front Immunol. 2022 Oct 4;13:1010835. doi: 10.3389/fimmu.2022.1010835. eCollection 2022. Front Immunol. 2022. PMID: 36268028 Free PMC article.
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults.
Assantachai P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, Muangpaisan W, Phannarus H, Saichompoo RB, Sura-Amonrattana U, Wongprompitak P, Toh ZQ, Licciardi PV, Srisutthisamphan K, Chokephaibulkit K. Assantachai P, et al. Among authors: niyomnaitham s. J Infect Dis. 2023 Oct 3;228(7):868-877. doi: 10.1093/infdis/jiad133. J Infect Dis. 2023. PMID: 37141388 Free PMC article. Clinical Trial.
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women.
Chayachinda C, Watananirun K, Phatihattakorn C, Anuwutnavin S, Niyomnaitham S, Phongsamart W, Lapphra K, Wittawatmongkol O, Rungmaitree S, Jansarikit L, Boonnak K, Wongprompitak P, Senawong S, Upadhya A, Toh ZQ, Licciardi PV, Chokephaibulkit K. Chayachinda C, et al. Among authors: niyomnaitham s. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228670. doi: 10.1080/21645515.2023.2228670. Epub 2023 Jul 13. Hum Vaccin Immunother. 2023. PMID: 37439770 Free PMC article. Clinical Trial.
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
Angkasekwinai N, Niyomnaitham S, Sewatanon J, Phumiamorn S, Sukapirom K, Senawong S, Toh ZQ, Umrod P, Somporn T, Chumpol S, Ritthitham K, Jantraphakorn Y, Srisutthisamphan K, Chokephaibulkit K. Angkasekwinai N, et al. Among authors: niyomnaitham s. Asian Pac J Allergy Immunol. 2023 Jul 16. doi: 10.12932/AP-160123-1533. Online ahead of print. Asian Pac J Allergy Immunol. 2023. PMID: 37466962 Free article.
19 results